In this piece, we will take a look at the ten worst ARK stocks to buy according to short sellers.
Investing comes in all sizes and flavors. For the risk averse investors that are looking for steady payouts or long term stability, value and dividend paying stocks are the way to go. For others, that are looking for serious returns, growth stocks are preferred at the cost of higher risk.
One hedge fund that takes a pure play aggressive growth stock investment approach is Cathie Wood’s ARK Investment. Ark is known for investing in stocks that it believes are or will prove to be disruptive. This strategy has seen the firm’s returns somewhat tailored to the broader economic and stock market environment. For instance, during the coronavirus pandemic when interest rates were at historic lows and internet stocks were booming, Ark Investment returned 20% in 2020. This led to Wood giving an interview with Bloomberg where she stressed that her firm kept a multi year investment horizon in mind when buying stocks. She also shared that Ark’s investment approach was thematic in nature, and as opposed to big tech stocks that had reaped most of their returns already, the hedge fund was focusing on sectors that it believed held the most promising futures. Some of the sectors that were on her mind were DNA companies, robotics, blockchain, energy storage, and everyone’s favorite, artificial intelligence.
While we’ll get to the other end of Wood’s returns being tailored to the economy or the broader stock market, artificial intelligence brings another controversial decision that her firm has made to our mind. This was when her firm decided to completely exit Wall Street’s favorite artificial intelligence stock, which ranks 14th on our list of Morgan Stanley’s Highest Conviction Stocks: Top 20 Stocks To Buy and is a multi trillion dollar firm known for its AI GPUs. What do Wood and this stock have in common? Well, her fund cut its stake in the firm by 63% in Q4 2022. Back then, the shares were trading at a post split valuation of $14.61 or at $146 pre split. By June 2024, the stock had soared to $1,131 (pre split) meaning that Ark had missed out on a whopping $854 million in gains.
Commenting on her decision later on, she shared that “we also redeployed a, a good chunk of” the proceeds from the stock sales, “certainly at the later stage of our selling” into the fast growth stock that’s ranked 6th in our list of the 10 Best Fast Growth Stocks To Buy Now. This stock “last year was actually up more” than the GPU company, said Wood, adding that if the GPU stock is “to continue working, we must see this pull through into more of the tech stack. Otherwise, we have some productivity tools and, uh, assistants, that are working at the periphery of organizations but are not getting at, uh, what Dario, the CEO of Anthropic, calls the central part of organizations.”
As to buying the shares again, Wood hasn’t ruled out buying it back again, she will only make such a decision “if there were a significant price correction around, around, let’s say around an inventory” correction. The investor then shared examples of historic inventory corrections especially when the cryptocurrency market underwent this correction and a glut led to the stock dropping by “two thirds in one quarter.”
Cycling back, the stock market’s recent performance has also made an impact on Wood’s portfolio. Looking at the performance of her top ten stock picks during Q4 2020 and analyzing their gains or losses by the close of Q1 2024, only four stocks remained in her portfolio. By the close of H1 2024, these stocks were all in the red. The worst performer amongst them had lost 86% since the start of 2021, while the others’ losses ranged between 73% to 39%. If you’re hoping that the stocks that were eliminated might have fared better, you’d be wrong. Not only are all six in the red, but several have lost more than 80% while one has been delisted from the NASDAQ exchange.
This performance would seem to imply that Wood has lost her stock picking mojo. However, this clearly isn’t the case. With the second quarter of 2024 hedge fund filings out, we can see which Cathie Wood stocks have done well and which have faltered. Analyzing the year to date performance of the top ten Cathie Wood stocks shows that six are in the green. This is noticeably better than how her fourth quarter of 2020 stocks have fared since then. These stocks’ performance ranges between 2.21% to 81.42%, with the top three performers up by 46.91%, 64.19%, and 81.42%, respectively. In the same order, these firms belong to software, financial markets, and data analysis industries and they rank 8th, 6th, and 9th in Cathie Wood’s Q2 2024 investment portfolio.
Before we head to our list of the worst Ark stocks to buy when considering short seller sentiment, it’s also important to understand the rationale behind the fund’s picking strategy. In its annual research report, the fund is still bullish on disruptive innovation. It believes that returns generated by firms that are part of this trend could exceed 40% on an annualized basis during the next seven years for a final market cap of $220 trillion. Ark also believes that AI training costs could drop by 75% per year by 2030, and the market for generalizable, or humanoid, robots could cross $24 trillion in annual revenue. Morgan Stanley seems to agree, and you can read more by checking out $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley.
Cathie Wood of ARK Investment Management
Our Methodology
To make our list of the worst Ark stocks to buy according to short sellers, we ranked 120 stocks out of the 180 present in Ark Invest’s Q2 2024 SEC filings by the percentage of shares outstanding that were sold short and selected the stocks with the highest percentage.
For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
10. Vuzix Corporation (NASDAQ:VUZI)
Short Interest as % of Shares Outstanding: 13.82%
Number of Hedge Fund Investors In Q2 2024: 11
Ark Invest’s Q2 2024 Stake: $48.4 million
Vuzix Corporation (NASDAQ:VUZI) is a small electronics company that sells wearable computing devices and logistics solutions. Since it is in the early stages of commercialization, the firm is yet to turn a profit or earn an operating income. The firm currently generates revenue from smart glasses, and since it has little penetration in the consumer market, Vuzix Corporation (NASDAQ:VUZI)’s revenue is dependent on business customers for the time being. This means that the firm often sees fluctuating sales that rise and drop depending on whether it has received and recognized revenue from orders. However, one advantage for Vuzix Corporation (NASDAQ:VUZI) that stems from selling to large companies is that it can charge high average selling prices for the products. This offers it a considerable advantage over the consumer market, where well funded firms such as Facebook parent Meta already sell smart glasses, headsets, and similar hardware to force new entrants like Vuzix Corporation (NASDAQ:VUZI) be price competitive and sacrifice margins in the process. Vuzix Corporation (NASDAQ:VUZI)’s products are quite technically challenging to manufacture as well which requires it to have a beefy balance sheet to fund development.
Vuzix Corporation (NASDAQ:VUZI)’s management shared details for new contracts that could inject fresh life into its income statement during the Q2 2024 earnings call:
“One of them is on the defense side and one of them is a commercial opportunity. On the defense side, it’s probably going to be $5,000 to $7,000 per asset that we sell into that piece of business. And the first sort of salable or opportunity that it’s going to be filling is upwards of 2,000 pieces. So, like, do the math, it’s pretty easy. It’s $10 million to $14 million worth of business, I think, for the — and that solution that we’ve built can go into a multiple different places and this is just one spot that it was initially designed for. So that’s a pretty significant revenues for just one project. And then, the other one is an imaging system for temperature-related inside of enterprise operations or it’s like maybe places where there’s hot equipment around, motors that might get hot.
You put the glasses on and they can help you determine whether or not there’s maintenance or safety issues or whatever. And that’s an enterprise product that could have significant volumes associated with it, upwards of 20,000 to 30,000 pieces. I’m not sure when that’s going to roll out in that kind of volumes, quite frankly. We’re hoping that it starts to move by the end of this year.”
9. Twist Bioscience Corporation (NASDAQ:TWST)
Short Interest as % of Shares Outstanding: 15.72%
Number of Hedge Fund Investors In Q2 2024: 28
Ark Invest’s Q2 2024 Stake: $302 million
Twist Bioscience Corporation (NASDAQ:TWST) is a medical raw materials supplier that caters to the needs of the DNA and gene editing industry. Wood had owned a $850 million stake in the firm in Q4 2020, and since then, the stock has lost roughly 60%. Twist Bioscience Corporation (NASDAQ:TWST) targets the highly growing, and highly risky, gene editing industry. The potential of gene editing was clear in December 2023 when the FDA approved two gene editing based sickle cell treatments. Along with medicine, gene editing has a host of use cases in other industries such as agriculture and biotechnology. This creates a large TAM for Twist Bioscience Corporation (NASDAQ:TWST), but at the same time, the nascent nature of all these industries means that unless the markets that the products made with Twist Bioscience Corporation (NASDAQ:TWST)’s products grow significantly, the firm will remain a small time player in the healthcare industry. Since it’s a raw materials provider, the firm’s orders typically take place early in the year, which creates revenue volatility.
Twist Bioscience Corporation (NASDAQ:TWST) is busy expanding its product portfolio. During the Q3 2024 earnings call, the firm shared:
“Importantly, we continue to launch new products that build off of our Express Genes portfolio and infrastructure. In May, we launched Multiplexed Gene Fragments with direct synthesis of DNA up to 500 base pairs. This direct synthesis length along with pooling of fragments enable our customers to pursue myriad applications. Some examples include encoding entire viable regions for antibody discovery and encoding entire functional domains of proteins for enzyme engineering, both of which are very useful for parallel screening of AI or ML-generated sequences. In addition, two important applications of this 500 base pairs length enable customers to encode mRNA sequences for personalized therapy or encode multiple guide RNA sequences within a single framework for complex CRISPR screens.
These are just four examples of diverse applications for this innovative product that showcase how we augment our processes continuously to drive innovation and for new products while expanding our infrastructure capacity. Also building onto the Express workflow, in July, we introduced Express Antibodies, both for CHO and HEK293, the two most commonly used cell lines for the antibody discovery and optimization cycle. Multiplexed Gene Fragments and Express Antibodies illustrate the benefit of making all of our DNA on the Express timeline as we do not need to cut the line for particular customers. In addition to growth for our existing portfolio of products, including Express Genes, we will continue to add products that leverage our rapid manufacturing.
These products will target areas of the life science market that we do not serve today and have the potential to expand our share of wallet with existing customers as well as open up new market opportunities.”